Marina Coppola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marina Coppola has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Giorgia Zorzetto
Veneto Oncology Institute
3 shared publications Agnese Casarin
Veneto Institute of Oncology – IOV IRCCS
2 shared publications- Alberto Russi
Veneto Institute of Oncology – IOV IRCCS
2 shared publications Alessandro Giuriola
Veneto Institute of Oncology – IOV IRCCS
2 shared publications- Camilla Saran
Pharmacy Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
2 shared publications Francesca Pipitone
Veneto Institute of Oncology – IOV IRCCS
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 19 (1)
Toward standardised management of Oral Anticancer Agents: real-world evidence to inform technical standards and shared models of care
- 18 November 2026
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 19 (1)
Open AccessToward standardised management of Oral Anticancer Agents: real-world evidence to inform technical standards and shared models of care
- Open Access
- 6 November 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (1) , 87-95
Institutional single-center cost-opportunity analysis of disposable vs. reusable cystoscopes in a referral oncology center
Cystoscopy is a high-frequency endoscopic procedure in both oncologic and non-oncologic urology. Healthcare systems are increasingly required to adopt evidence-based and sustainable strategies for device management. This institutional cost-opportunity analysis compared disposable and reusable cystoscope devices in a high-volume oncology center. Retrospective real-world data on disposable use were combined with theoretical modeling for reusable systems under three operational scenarios: disposable, reusable with standard sterilization, and reusable with urgent sterilization, each analyzed in optimized and maximal-cost conditions. Disposable cystoscopes cost €188,75.00 per procedure, halved procedural time (15 vs. 30 minutes), and ensured workflow continuity. Reusable systems were economically sustainable only under optimized reprocessing (two cystoscopes per cycle, €180,88.00 per procedure). Under urgent or single-scope sterilization, per-procedure costs increased to €198,88.00 with annual excesses of up to €79,820.88 compared to disposable systems. Disposable devices minimized downtime and logistical complexity, particularly in high-demand settings. Reusable cystoscopes achieve economic sustainability only when supported by standardized, high-efficiency workflows, while disposables provide flexibility and reliability in routine and urgent care. Despite its single-center, retrospective design, this framework provides transferable insights for healthcare institutions aiming to align cost management, service quality, and sustainability in cystoscopic practice. Future multicentric studies are warranted to validate these findings across diverse organizational settings.
- 6 November 2025
- Published by Taylor & Francis in Expert Review of Pharmacoeconomics & Outcomes Research
- Vol. 26 (1) , 87-95
Open AccessInstitutional single-center cost-opportunity analysis of disposable vs. reusable cystoscopes in a referral oncology center
Cystoscopy is a high-frequency endoscopic procedure in both oncologic and non-oncologic urology. Healthcare systems are increasingly required to adopt evidence-based and sustainable strategies for device management. This institutional cost-opportunity analysis compared disposable and reusable cystoscope devices in a high-volume oncology center. Retrospective real-world data on disposable use were combined with theoretical modeling for reusable systems under three operational scenarios: disposable, reusable with standard sterilization, and reusable with urgent sterilization, each analyzed in optimized and maximal-cost conditions. Disposable cystoscopes cost €188,75.00 per procedure, halved procedural time (15 vs. 30 minutes), and ensured workflow continuity. Reusable systems were economically sustainable only under optimized reprocessing (two cystoscopes per cycle, €180,88.00 per procedure). Under urgent or single-scope sterilization, per-procedure costs increased to €198,88.00 with annual excesses of up to €79,820.88 compared to disposable systems. Disposable devices minimized downtime and logistical complexity, particularly in high-demand settings. Reusable cystoscopes achieve economic sustainability only when supported by standardized, high-efficiency workflows, while disposables provide flexibility and reliability in routine and urgent care. Despite its single-center, retrospective design, this framework provides transferable insights for healthcare institutions aiming to align cost management, service quality, and sustainability in cystoscopic practice. Future multicentric studies are warranted to validate these findings across diverse organizational settings.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Real‐Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center
Purpose: Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020‐2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs. Methods: Data from the real‐world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression‐free survival (PFS) and overall survival (OS). Results: A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single‐agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS. Conclusion: A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.
- 1 January 2025
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 2025 (1)
Open AccessReal‐Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center
Purpose: Inappropriate use of antibiotics contributes to the increase in antimicrobial resistance with negative health safety implications. Global health organizations have promoted projects to improve proper and rational use of antibiotics. Recent studies show how antibiotics can also influence the efficacy of immune checkpoint inhibitors (ICIs) treatment in cancer patients. This work analyzes the impact of concomitant antibiotic therapy in patients affected by skin, lung, and kidney cancer, who started immunotherapy in 2020‐2021 at Veneto Institute of Oncology IRCCS. The aim of this study is to evaluate clinical outcomes, treatment efficacy, discontinuation causes, and occurrence of adverse drug reactions in cancer patients treated with ICIs. Methods: Data from the real‐world retrospective study were extracted from Territorial Pharmaceutical Care databases, medical records, and the AIFA registry. A descriptive analysis of the study population was performed, as well as of patient outcomes in terms of progression‐free survival (PFS) and overall survival (OS). Results: A total of 239 subjects affected by kidney (8%), lung (48%), and skin (44%) cancer were enrolled; of these, 50%, 32%, 9%, and 9% were treated with single‐agent nivolumab, pembrolizumab, atezolizumab, and cemiplimab, respectively. A total of 119 patients received concomitant antibiotic therapy. Median OS was 8.8 months (95% CI: 5.02–11.8) and 31.05 months (95% CI: 24.81–NA) in subjects with high and low antibiotic exposure, respectively. Multivariate subgroup analysis confirmed that high antibiotic exposure is an unfavorable factor also for median PFS. Conclusion: A prolonged exposure to antibiotics correlates with unfavorable outcomes in cancer patients undergoing concomitant immunotherapy. Thus, managing antibiotic exposure is fundamental for optimizing ICI treatment.
- Open Access
- 30 November 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 649, 123643
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations
- 30 November 2023
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 649, 123643
Open AccessProlonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations
- Open Access
- 1 January 2021
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 28 (1) , 16-17
Laparoscopic Technique for Discoid Resection of Rectal Endometriotic Nodules
- 1 January 2021
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 28 (1) , 16-17
Open AccessLaparoscopic Technique for Discoid Resection of Rectal Endometriotic Nodules